|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | G01N 33/53 | |
| A61K 38/18 | |||
| A61K 38/19 | |||
| A61P 3/06 | |||
| A61P 3/10 |
| (11) | Number of the document | 1444516 |
| (13) | Kind of document | T |
| (96) | European patent application number | 02793811.7 |
| Date of filing the European patent application | 2002-10-22 | |
| (97) | Date of publication of the European application | 2004-08-11 |
| (45) | Date of publication and mention of the grant of the patent | 2010-07-21 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2002/033875 |
| Date | 2002-10-22 |
| (87) | Number | WO 2003/034996 |
| Date | 2003-05-01 |
| (30) | Number | Date | Country code |
| 336394 P | 2001-10-22 | US |
| (72) |
DEPAOLI, Alex M., US
ORAL, Elif, Arioglu, US
TAYLOR, Simeon I., US
GARG, A., Univ. Texas Southwestern Medical Centre, US
|
| (73) |
THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM,
201 West 7th Street, Austin, Texas 78701,
US
Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, US The Government of the United States of America, represented by the Secretary, Department of Health and Human Services, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804, US |
| (54) | USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD OF DETERMINING PREDISPOSITION TO SAID TREATMENT |
| USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD OF DETERMINING PREDISPOSITION TO SAID TREATMENT |